These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 18349406

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J.
    J Clin Oncol; 2006 Aug 20; 24(24):3991-6. PubMed ID: 16921052
    [Abstract] [Full Text] [Related]

  • 5. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
    Loehberg CR, Jud SM, Haeberle L, Heusinger K, Dilbat G, Hein A, Rauh C, Dall P, Rix N, Heinrich S, Buchholz S, Lex B, Reichler B, Adamietz B, Schulz-Wendtland R, Beckmann MW, Fasching PA.
    Breast Cancer Res Treat; 2010 May 20; 121(1):101-10. PubMed ID: 20306293
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
    Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S.
    Cancer; 2005 May 15; 103(10):1996-2005. PubMed ID: 15825209
    [Abstract] [Full Text] [Related]

  • 9. Worry and risk perception of breast cancer in a prevention trial of low dose tamoxifen in midlife postmenopausal hormone users.
    Rondanina G, Puntoni M, Guerrieri-Gonzaga A, Marra D, Bonanni B, DeCensi A.
    Breast; 2017 Aug 15; 34():108-114. PubMed ID: 28570956
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Validation of a model predicting enrollment status in a chemoprevention trial for breast cancer.
    Yeomans Kinney A, Vernon SW, Shui W, Weber DV, Schell M, Vogel VG.
    Cancer Epidemiol Biomarkers Prev; 1998 Jul 15; 7(7):591-5. PubMed ID: 9681527
    [Abstract] [Full Text] [Related]

  • 12. Choices in cancer treatment: a qualitative study of the older women's (>70 years) perspective.
    Husain LS, Collins K, Reed M, Wyld L.
    Psychooncology; 2008 Apr 15; 17(4):410-6. PubMed ID: 17847124
    [Abstract] [Full Text] [Related]

  • 13. Cancer prevention trials and primary care physicians: factors associated with recommending trial enrollment.
    Battaglia TA, Ash A, Prout MN, Freund KM.
    Cancer Detect Prev; 2006 Apr 15; 30(1):34-7. PubMed ID: 16476525
    [Abstract] [Full Text] [Related]

  • 14. Stroke risk and tamoxifen therapy for breast cancer.
    Geiger AM, Fischberg GM, Chen W, Bernstein L.
    J Natl Cancer Inst; 2004 Oct 20; 96(20):1528-36. PubMed ID: 15494603
    [Abstract] [Full Text] [Related]

  • 15. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
    Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M.
    Cancer; 2004 May 01; 100(9):1800-6. PubMed ID: 15112259
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Understanding attitudes of older women toward hormone replacement therapy.
    Phelan EA, Buist DS, Anderson LA, Newton KM, Delaney KM, LaCroix AZ.
    Prev Med; 2001 Jan 01; 32(1):49-56. PubMed ID: 11162326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.